Thermalin is engineering new forms of insulin that will lower the burden of insulin use, increase patient adoption of and adherence to insulin therapy, improve patient lives and outcomes, and lower the cost of caring for people with Type 1 Diabetes (T1D) or Type 2 Diabetes (T2D).
Founded in 2010 based on pioneering work by Dr. Michael Weiss on the structure and function of insulin analogues, Thermalin is overcoming the limitations of existing insulin products by re-engineering the insulin molecule to be more stable and to act more selectively. Thermalin’s formulations of these new molecules enable new delivery devices and systems that will transform lives.  On September 28, Thermalin announced a worldwide collaboration with Sanofi on two of its insulin programs as well as a $17.5M Series A Financing that is being led by Sanofi.

Open Positions

Loading...
No results matched your search

Research Associate/Industry Postdoc Protein Biochemistry

Cleveland, OH

Objectives Biophysical characterization of insulin analogs and formulations Reports to VP, Research & Development Responsibilities ·    Biophysical characterization (e.g., unformulated an ...

learn more...

Laboratory Associate/Research Associate - Bioassays

Cleveland, OH

Objectives Performing cell-based assays and immunoassays (ELISA) for preclinical characterization of insulin analogs Reports to:          Senior Scientist-Bioassays Responsibilities ·    Independently plan and reliably conduct studies in a fast-paced environment ...

learn more...

Laboratory Associate -ELISA

Cleveland, OH

Objectives Performing cell-based assays and immunoassays (ELISA) for pharmacokinetic and screening studies Reports to:          Managing Scientist-Bioassays Responsibilities ·      High-throughput ELISA and other immunoassays ·      Cell culture and cell-b ...

learn more...

Laboratory Associate/Research Associate - Protein Purification

Cleveland, OH

Company Background Thermalin Inc. is developing a pipeline of patent pending insulin analogs that address significant unmet needs in the rapidly growing insulin market ($17B today, $70B expected worldwide by 2030).  Founded on a portfolio of new insulin analogs invented by Dr. Michael Weiss, Chairman Emeritus of Biochemistry at Case Western Reserve Medical School and Director ...

learn more...